食管鳞癌组织中miR-129与患者预后的关系分析  

Assessment of left ventricular twist in patients with type 2 diabetes mellitus using two-dimensional ultrasound speckle tracking imaging

作　　者：黄敬垣[1] 杨性安 叶萌[1] 杨继东[1] 洪勇强[1] 郑哲岚[4] 何娴[2] 

机构地区：[1]浙江医院超声科,杭州310013 [2]中国人寿保险股份有限公司杭州市分公司卫生所 [3]折江省台州医院超声科 [4]浙江大学医学院附属第一医院超声科

出　　处：《浙江医学》2013年第4期256-258,共3页Zhejiang Medical Journal

摘　　要：目的探讨超声二维斑点追踪显像（STI）技术对2型糖尿病患者左室心肌扭转运动的诊断价值。方法选取2型糖尿病患者67例，根据LVEF分为左心收缩功能正常组（A组，LVEF〉50％）33例、左心收缩功能减低组（B组，LVEF〈50％）34例，另择同期体检健康者33例作为对照组。采用常规超声及STI技术对3组对象的左室扭转情况进行定量分析，并比较分析。结果A组患者左室扭转角度峰值（Peaktw）、主动脉瓣关闭时间点扭转角度（AVCtw）、二尖瓣开放时间点扭转角度（MVOtw）较对照组显著升高（P〈0．01）；B组患者Peaktw、AVCtw、MVOtw较对照组及A组显著降低（P〈0．01）。与对照组比较，2型糖尿病患者等容解旋比例（IUR）、解旋率（UntwR）减低（P〈0．05），而解旋减半时间（UHT）即明显延迟（P〈0．01），与A组比较，B组患者等容解旋比例、解旋率降低（P〈005），而解旋减半时间明显延迟（P〈0．01）。结论超声二维斑点追踪显像技术能够早期识别2型糖尿病患者的心功能异常变化。Objective To evaluate the characteristics of left ventricular twist in patients with type 2 diabetes using two-dimensional speckle tracking imaging （ STI ）. Methods Sixty seven patients with type 2 diabetes were divided into two groups： 33 cases with normal left ventricular ejection fraction （LVEF） （LVEF〉50%, group A） and 34 cases with abnormal LVEF （LVEF〈50%, group B）. Thirty three normal subjects served as controls, The left ventricular twist was quantitatively analyzed with STI technology in 3 groups. Results The Peaktw, AVCtw and MVOtw values in group A were significantly elevated than those in normal controls （P〈0.01）; however, Peaktw, AVCtw and MVOtw in group B were lower than those in group A and normal controls （P〈0.01）. The IUR and UntwR in diabetic patients were lower than those in normal controls （P〈0.05） and UHT was significantly delayed （P〈 0.01）. There were significant differences in IUR, UntwR and UHT values between two groups of diabetic patients （P〈0.05, P〈 0.01, respectively）. Conclusion Two-dimensional speckle tracking imaging technology can be used for early recognition of abnormal cardiac function in patients with type 2 diabetes mellitus.

关 键 词：超声心动描记术 超声二维斑点追踪显像技术 扭转 糖尿病 左心室功能 

分 类 号：R735.1[医药卫生—肿瘤]